Description: SP600125 (JNK Inhibitor II) is a JNK inhibitor that inhibits JNK1, JNK2, and JNK3 (IC50=40/40/90 nM) with oral potency, reversibility, and ATP-competitive properties. SP600125 inhibits autophagy and induces apoptosis. Target: Apoptosis, Aurora Kinase, Autophagy, Ferroptosis, JNK, Trk receptor....

SP6000125 is a pan-inhibitor of JNK (IC50s = 0.04, 0.04, and 0.09 µM for JNK1, -2, and -3, respectively). It is greater than 300-fold selective for these enzymes over a panel of 17 additional kinases at 10 µM. SP6000125 reduces LPS-induced production of IL-1beta, IL-8, and TNF-alpha in isolated human peripheral...

Novel, potent and selective JNK-1,-2, and -3 inhibitor (Ki=0.19uM). SP600125 is an ATP-competitive reversible inhibitor with >20-fold selectivity vs. a range of kinases and enzymes tested. In cells, SP600125 caused a dose-dependent inhibition of the phosphorylation of c-Jun, the expression of inflammatory genes...

SP600125 is an orally active, reversible and ATP-competitive broad-spectrum JNK inhibitor for JNK1, JNK2 and JNK3 (IC50 = 40nM, 40nM and 90nM, respectively). In Jurkat T cells, SP600125 suppressed the phosphorylation of c-Jun with IC50 of 5-10 µM. It has 10-fold greater selectivity against MKK4, 25-fold greater...